The anti-PD-1-IL2 fusion protein is then conceived to increase the binding of IL2 mutein to PD1+ TILs, thereby enabling low toxicities due to reduced IL2 binding to its receptors in peripheral immune cells while boosting PD1+ tumor antigen-specific T cells in the TME. The gene discussed is PDCD1; the disease is neoplasm.